Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease

Genta Ito1, Naoko Utsunomiya-Tate1

  • 1Department of Biomolecular Chemistry, Faculty of Pharma-Sciences, Teikyo University, Tokyo 173-8605, Japan.

Biomolecules
|May 27, 2023
PubMed

Insights

Leucine-rich repeat kinase 2 (LRRK2) mutations are linked to Parkinson's disease (PD). This review explores how LRRK2 mutations impact its function, leading to varied PD pathologies.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Leucine-rich repeat kinase 2 (LRRK2) is a protein kinase involved in Rab protein regulation.
  • LRRK2 is genetically linked to familial and sporadic Parkinson's disease (PD).
  • The precise pathogenic mechanisms of LRRK2 in PD remain unclear.

Purpose of the Study:

  • To summarize clinical and pathological features of LRRK2-associated PD.
  • To elucidate the impact of LRRK2 mutations on LRRK2 molecular function and structure.
  • To provide a historical overview of LRRK2 in PD pathogenesis for researchers new to the field.

Main Methods:

  • Literature review of clinical and pathological studies on LRRK2 mutations in PD.
  • Analysis of research on LRRK2 protein function and structural changes due to mutations.
  • Synthesis of historical data regarding LRRK2 and PD.

Main Results:

  • LRRK2 mutations cause PD with clinical symptoms often indistinguishable from sporadic PD.
  • Pathological manifestations in LRRK2-mutant PD brains show significant variability compared to sporadic PD.
  • Mutations alter LRRK2 function and structure, potentially explaining pathological differences.

Conclusions:

  • Understanding LRRK2's role is crucial for deciphering PD pathogenesis.
  • Variability in LRRK2 pathology highlights the complexity of LRRK2-associated PD.
  • This review offers a foundational understanding of LRRK2 mutations in PD.

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...